San Diego-based Aegea Biotechnologies Inc. and Tauriga Sciences Inc., of New York, reported progress on the development of a rapid, lateral flow, point-of-care COVID-19 diagnostic test. Aegea has produced the initial prototypes of the portable, disposable devices for the Lateral Flow COVID-19 test and successfully completed initial tests of the device. To expedite development and commercialization, Aegea has hired George Maltezos as chief engineer. The companies are developing the test under a collaborative agreement.

Nuth, Netherlands-based startup Aminoverse NV has launched its Aelysa Corona Antibody Test Kit, which utilizes dry blood spot technology to test one drop of blood for both conventional and neutralizing antibodies to COVID-19.

Bioivt, of Westbury, N.Y., has expanded its inventory of COVID-19 specimens for diagnostic, drug and vaccine research.

Ciox Health LLC, of Alpharetta, Ga., has acquired biomedical natural language processing company, Medal Inc., of San Francisco. Financial terms were not disclosed.

Edinburgh, Scotland-based Current Health Ltd. reported that its remote patient monitoring and virtual care platform has been listed on Spark (RM6094), a dynamic purchasing system provided by the Crown Commercial Service.

Cytosorbents Corp., of Monmouth Junction, N.J., said the data monitoring committee of the REFRESH 2-AKI clinical trial has recommended the study be resumed, following a favorable review of safety data. The study – which was voluntarily paused in November 2019 as it transitioned to a new contract research organization – is assessing the use of two Cytosorb cartridges in parallel during cardiac surgery to reduce the incidence or severity of acute kidney injury 48 hours after surgery in two populations undergoing either valve replacement surgery or aortic reconstruction with hyperthermic cardiac arrest.

Tel Aviv-based Datos Health Ltd. is partnering with Vaica Medical, also of Tel Aviv, to include medication adherence information as part of Datos’ offering of analyzed data relating to a patient’s overall status.

Edifecs Inc., of Bellevue, Wash., will receive a significant growth investment from TA Associates and Francisco Partners, under a definitive agreement signed by the private equity firms. Financial terms of the transaction, which is expected to close in the third quarter of 2020, were not disclosed.

San Diego-based Exagen Inc. said that all Avise test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, MTX and HCQ) will be a contracted covered service with Tricare East managed support contractor Humana Military to optimize patient care. The agreement will make Avise tests available to about 6 million beneficiaries.

Guided Therapeutics Inc., of Peachtree Corners, Ga., has submitted a clinical study protocol to the FDA to support marking of its Luviva Advanced Cervical Scan in the U.S.

Rochester, N.Y.-based Heart Health Intelligence, the developer of The Heart Seat, a cloud-connected self-contained toilet seat-based cardiovascular monitoring system, has joined the American Heart Association Center for Health Technology & Innovation’s Innovators’ Network.

The international Ireceptor Plus consortium is offering access to 200 million immune sequences of T and B cell receptor repertoires from COVID-19 patients to researchers, drug companies and the scientific community.

Neuroone Medical Technologies Corp., of Eden Prairie, Minn., retired roughly $3.3 million in debt during the month of July 2020, strengthening the company’s balance sheet. The company is now transitioning to advancing commercial planning, building its financial infrastructure and new product development.

Orbis Diagnostics Ltd., of Auckland, New Zealand, has convened a team of New Zealand and American scientists to develop a rapid, high-volume, low-cost and highly accurate quantitative immune testing platform to provide COVID-19 mass immunity testing, with the aim of enabling quarantine-free international travel.

Osi Systems Inc., of Hawthorne, Calif., said its Optoelectronics division has received an order for approximately $5 million from a leading health care original equipment manufacturer to provide optical sensors for use in medical devices.

Seattle-based startup Saykara Inc. said the Midwest Institute for Minimally Invasive Therapies has added the company’s mobile artificial intelligence assistant to its toolkit of technology solutions.

Sema4, of Stamford, Conn., said it has increased capacity to process up to 15,000 COVID-19 viral tests per day in its lab in Connecticut. The company’s offerings are available to governmental organizations that want to offer testing for residents and employees. Results are provided within 24-48 hours of receiving the sample for the test.

Truework, a San Francisco-based startup focused on employment and income verification, reported a partnership with Hims Inc. (dba Hims & Hers), of San Francisco. The companies are working together to give the employees of Truework's partners access to COVID-19 testing through the Hims & Hers telehealth platform.

Tscan Therapeutics Inc., of Waltham, Mass., said pre-published data was posted on identifying the precise targets of T cells isolated from COVID-19 convalescent patients. Using its T cell target identification technology, Tscan mapped the memory CD8+ T cell responses of convalescent COVID-19 patients. Immunodominant targets were shared among patients with the same human leukocyte antigen type and were primarily located outside the spike protein. These findings have been submitted for scientific review and publication.

Twist Bioscience Corp., of South San Francisco, reported the availability of two new SARS-CoV-2 antibody panels designed for research use only. The Twist anti-SARS-CoV-2 S1 Antibody Panel includes 32 human antibodies that bind with picomolar to nanomolar affinity to S1 spike protein on the SARS-CoV-2 virus. The Twist Human anti-ACE2 Antibody Panel includes 48 antibodies that bind with picomolar to nanomolar affinity to the extracellular domain of the ACE2 receptor on human cells.